Form 4: Sutro Biopharma Director Daniel H. Petree Granted 50,000 Stock Options

Sutro Biopharma, Inc. (STRO) Director Daniel H. Petree has been granted 50,000 stock options with an exercise price of $0.85, aligning his interests with shareholders.

Summary

• Daniel H. Petree, a Director of Sutro Biopharma, Inc. (STRO), was granted 50,000 stock options.
• The transaction date for this grant was June 6, 2025.
• The exercise price for these stock options is $0.85 per share.
• The options will vest at a rate of 8.33% of the total shares monthly, commencing on July 6, 2025.
• Full vesting (100% of total shares) will occur on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026.
• The vesting is contingent upon Mr. Petree's continued provision of service to Sutro Biopharma on each vesting date.
• The expiration date for these stock options is June 6, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's financial interests with the company's performance and shareholder value. It signals confidence from the company in its leadership and future prospects, although it does not directly reflect operational or financial results.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the director benefits from an increase in the company's stock price.
• The exercise price of $0.85 is significantly below the current market price (implied, as options are typically granted at or above market price at grant, but this is a very low exercise price, suggesting it might be a legacy grant or a specific type of compensation, though the document doesn't specify the grant date's market price).
• The long expiration date of June 6, 2035, provides ample time for the options to become in-the-money and for the director to realize value.

Future Outlook

The document details the vesting schedule for the granted stock options, indicating that they will vest monthly starting July 6, 2025, and be fully vested by the earlier of the company's 2026 annual stockholders meeting or June 6, 2026, subject to continued service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of equity compensation to attract and retain talent, and to align the interests of directors with long-term shareholder value creation. This is a standard mechanism for incentivizing leadership in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in the biotech sector, which often relies on equity-based incentives.
• The vesting schedule, tied to continued service and a specific future date or event (annual meeting), is typical for such grants, ensuring retention and long-term commitment.
• The exercise price of $0.85 is notably low, which could indicate it's a legacy grant from a much earlier period, or a specific type of incentive option. Without the grant date's market price, a direct comparison to typical 'at-the-money' or 'in-the-money' grants is limited, but such a low price suggests significant potential upside for the director if the stock performs well.

Related Party Transactions

• The grant of 50,000 stock options to Daniel H. Petree, a Director of Sutro Biopharma, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The option grant aligns the director's incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting employees, such compensation practices for leadership can reflect the company's overall approach to incentivizing performance.

Next Steps

• Monthly vesting of 8.33% of the granted options commencing July 6, 2025.
• Full vesting of options by the earlier of Sutro Biopharma's 2026 annual stockholders meeting or June 6, 2026.
• Potential exercise of vested options by Daniel H. Petree before the expiration date of June 6, 2035.

Key Dates

Keywords

Sutro Biopharma, STRO, Stock Option, Insider Transaction, Director Compensation, Equity Grant, SEC Form 4, Daniel H. Petree